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Abstract
Neuroinvasive viruses, such as alpha herpesviruses (αHV) and rabies virus (RABV), initially
infect peripheral tissues, followed by invasion of the innervating axon termini. Virus particles
must undergo long distance retrograde axonal transport to reach the neuron cell bodies in
the peripheral or central nervous system (PNS/CNS). How virus particles hijack the axonal
transport machinery and how PNS axons respond to and regulate infection are questions of
significant interest. To track individual virus particles, we constructed a recombinant RABV
expressing a P-mCherry fusion protein, derived from the virulent CVS-N2c strain. We stud-
ied retrograde RABV transport in the presence or absence of interferons (IFN) or protein
synthesis inhibitors, both of which were reported previously to restrict axonal transport of
αHV particles. Using neurons from rodent superior cervical ganglia grown in tri-chambers,
we showed that axonal exposure to type I or type II IFN did not alter retrograde axonal trans-
port of RABV. However, exposure of axons to emetine, a translation elongation inhibitor,
blocked axonal RABV transport by a mechanism that was not dependent on protein synthe-
sis inhibition. The minority of RABV particles that still moved retrograde in axons in the pres-
ence of emetine, moved with slower velocities and traveled shorter distances. Emetine’s
effect was specific to RABV, as transport of cellular vesicles was unchanged. These findings
extend our understanding of how neuroinvasion is regulated in axons and point toward a
role for emetine as an inhibitory modulator of RABV axonal transport.
Author summary
Rabies virus (RABV) and alpha herpesviruses (αHV) (e.g. herpes simplex virus) evolved
to enter the nervous system efficiently each time they infect a host. In most mammals,
RABV reaches the brain, causing a fatal encephalitis. Whereas, αHV remain in the periph-
eral nervous system in a quiescent but reactivatable state. Despite distinct clinical out-
comes, both RABV and αHV must invade axons and repurpose the axon transport
machinery to travel long distances toward the neuronal cell bodies where virus replication
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occurs. How virus particles hijack the transport machinery and how axons respond to and
regulate infection are questions of significant interest. We investigated how axonal RABV
transport is regulated by exposing axons to interferons or protein synthesis inhibitors,
both of which restrict transport of αHV particles. Unlike αHV infection, exposure of iso-
lated axons to interferons has no effect on RABV neuroinvasion. However, RABV trans-
port is blocked by axonal exposure to the translation elongation inhibitor, emetine, via a
mechanism that does not depend on protein synthesis inhibition. The effect of emetine is
not due to a global inhibition of axon transport because emetine does not limit axonal
transport of cellular vesicles. Therefore, emetine may be a novel inhibitory modulator of
RABV axonal transport.
Introduction
Unlike most nervous system pathogens, which are either accidental or opportunistic, some
neuroinvasive viruses have evolved strategies to enter and exit the nervous system. One suc-
cessful strategy is that of rabies virus (RABV), a neuroinvasive human and animal pathogen of
the Rhabdoviridae family. A zoonotic rabies infection begins with the bite of an infected animal
into a muscle, followed by spread of virus particles through peripheral nervous system (PNS)
somatic motor neurons and into the central nervous system (CNS). Spread of the infection
from the CNS to salivary glands facilitates transmission to other hosts [1]. Nevertheless, the
end result of CNS infection is a fatal encephalitis in humans and most mammals. A distinct
but equally effective strategy is used by alpha herpesviruses (αHV) of the Herpesviridae family
(e.g. human herpes simplex virus type 1 and 2 (HSV-1 and 2) and swine pseudorabies virus
(PRV)) in their natural and non-natural hosts. These viruses replicate in peripheral epithelia
prior to invading the innervating PNS neurons where they establish life-long latent infections.
Unlike RABV, αHV rarely spread to the CNS in immunocompetent natural hosts. However,
latent αHV infections undergo stress-induced reactivation, which can lead to peripheral her-
petic lesions (e.g. cold sores) that facilitate inter-host spread. Despite their distinct clinical
pathologies, both RABV and αHV must invade axons, something most viruses do not do. In
addition, the infectious particles must travel long distances to reach the viral replication sites
in the PNS/CNS cell bodies. How these distinct neuroinvasive viruses infect the nervous sys-
tem efficiently remains a question of significant interest.
Due to the highly polarized nature of PNS neurons, axons function as molecular highways
for long distance transport of various cellular cargos including proteins, RNAs, vesicles, and
organelles [2]. Active transport between axon termini and cell bodies relies on microtubule-
based molecular motors. In axons, cargos are transported away from the cell body, in the
anterograde direction, by various microtubule plus-end directed kinesin motors. Cargos are
transported toward the cell body, in the retrograde direction, by a single microtubule minus-
end directed dynein motor that works in conjunction with dynein regulatory factors (e.g.
dynactin, Lis1, and NudE/NudEL) [3,4]. For efficient axonal invasion, virus particles must co-
opt the existing axonal transport machinery for long-distance retrograde transport, a process
that has not been fully elucidated.
The axon is a neuronal sub-compartment capable of sensing external stimuli and mounting
independent responses to local insults from the peripheral tissues including axon injury, infec-
tion, and exposure to trophic factors or pro-inflammatory cytokines [5–8]. Recently, it was
shown that αHV re-purpose the retrograde axon injury signaling response for efficient virus
particle transport in sympathetic superior cervical ganglia (SCG) axons. To do this, αHV
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infection induces rapid local translation of a subset of repressed axonal mRNAs without sup-
port from the connected cell bodies. Pharmacological inhibition of local protein synthesis
restricts axonal αHV infection [7]. Furthermore, exposure of SCG axons to the pro-inflamma-
tory cytokines, interferon-beta (IFNβ) or interferon-gamma (IFNγ), induced local antiviral
responses in axons that limited the number of αHV particles transported in the retrograde
direction [8]. These findings and others suggest that axons are independent sensors of periph-
eral αHV infection and raise the question if axons detect and respond to RABV infection in a
similar manner.
RABV enters axons primarily by clathrin-dependent receptor-mediated endocytosis, which
occurs when the viral envelope glycoprotein (G) binds to one of three known cell surface
receptors: neural cell adhesion molecule (NCAM), p75 neurotrophin receptor (p75NTR), and
n-acetylcholine receptor (nACHR) [9]. Viral particles in endosomes are transported retro-
grade until endosome acidification causes a conformational change in the G protein [10]. This
change leads to fusion of the viral and endosome membranes and release of nucleocapsids into
the cytosol. A majority of evidence suggests that RABV particles are released primarily in the
cell body after long distance retrograde transport inside endosomes [11,12]. Although the
RABV phosphoprotein (P) on the nucleocapsid was reported to bind directly to the LC8
dynein light chain [13,14], this interaction was not required for retrograde transport of RABV
or CNS infection [15].
RABV, similar to αHV, might alter the axonal environment to re-purpose the axon trans-
port machinery. Gluska et al. showed that RABV hijacks the neurotrophin signaling pathway
in sensory dorsal root ganglia (DRG) axons by binding to and internalizing with the nerve
growth factor (NGF) receptor, p75NTR [16]. Interestingly, RABV-containing endosomes
moved retrograde with greater velocity and processivity than NGF-containing endosomes.
However, the mechanism leading to faster retrograde transport of RABV-carrying vesicles
is not well understood, and it is not clear whether pharmacological agents could act locally
in PNS axons to regulate or block RABV transport. An additional complication was that
previous studies were conducted with attenuated vaccine strains, which may have different
transport properties than pathologic neurovirulent strains due to differences in their
glycoproteins.
In this report, we extend the current understanding of RABV axonal invasion and trans-
port by using a RABV P-mCherry-expressing recombinant derived from a neurovirulent
strain (CVS-N2c) that is more neurotropic and less neurotoxic than the attenuated strains
used previously [17]. Using a tri-chamber neuron culture system that physically separates
axons from cell bodies, we show that RABV particles enter SCG axons and are transported
efficiently in the retrograde direction. Unlike αHV infection, exposure of isolated axons to
IFNβ or IFNγ has no effect on RABV neuroinvasion. Again, unlike axonal infection by αHV,
RABV infection does not stimulate significant local protein synthesis. However, RABV
transport is blocked by axonal exposure to the translation elongation inhibitor, emetine.
Interestingly, emetine is the only protein synthesis inhibitor that blocked retrograde infec-
tion: Axonal treatment with cycloheximide or puromycin had no effect. The minority of
RABV particles that do move in the retrograde direction in the presence of emetine, move
with slower velocities and travel shorter distances. We find that the effect of emetine is not
due to a global inhibition of axon transport because emetine does not limit the proportion of
moving Rab5- or Rab7-positive vesicles in axons. Therefore, emetine must inhibit retrograde
RABV transport by a mechanism that is independent of cytosolic protein synthesis inhibi-
tion, and it may be a novel inhibitory modulator of RABV axonal transport. In summary,
these findings reveal that axons of PNS sympathetic neurons use distinct mechanisms to
detect and respond to αHV and RABV.
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Results
Construction of a CVS-N2c RABV recombinant for live-cell imaging in
PNS neurons
RABV axon transport studies were conducted previously with attenuated vaccine strains (i.e.
SAD B19) [18]. Attenuated strains display reduced neurotropism compared to virulent strains
due to differences in the glycoprotein, which dictates the axon entry and retrograde transport
properties of RABV [19,20]. To analyze neuroinvasion events by virulent RABV, we con-
structed a recombinant derived from the neuroinvasive CVS-N2c parental strain (Fig 1A)
[21]. The recombinant expresses a RABV phosphoprotein-mCherry fusion protein (P-
mCherry) that is incorporated into nucleocapsids to facilitate real-time visualization and track-
ing of single RABV particles. This P fusion was shown to be functional recently [22]. Prior to
constructing the recombinant virus, the G gene was deleted from the N2c strain to create a
spread-deficient virus (ΔG) that, when propagated on a G-complementing cell line, can infect
a single round of cells but cannot spread to uninfected cells.
RABV(ΔG) P-mCherry was recovered from cloned cDNA that was transfected into Neu-
ro2A mouse neuroblastoma (N2a) cells expressing the CVS-N2c G protein as described previ-
ously [23]. We refer to the G-complemented virus as RABV P-mCherry.
Single RABV P-mCherry particles can be visualized by fluorescence
microscopy
The protein composition of sucrose-purified RABV P-mCherry particles was verified using
SDS-PAGE and western blotting with anti-RABV G, N, M, and P antibodies (Fig 1B). We next
determined if sufficient P-mCherry protein was incorporated into nucleocapsids to visualize
individual RABV particles by fluorescence microscopy. Diluted supernatants from RABV P-
mCherry-infected, G-expressing N2a cells were spotted on glass coverslips. We observed red
fluorescent punctae of relatively uniform shape from infected cell supernatants (Fig 1C, see
also S1 Fig).
To determine the proportion of fully enveloped virions in the virus stock, particles on cov-
erslips were stained with an antibody recognizing the RABV G protein on the envelope surface
and green Alexa Fluor 488-conjugated secondary antibody. We observed green fluorescent
punctae that were similar in shape to the red punctae in our virus stocks. 68% of the red and
green punctae co-localized, suggesting that the majority of P-mCherry containing particles in
the virus stock are intact, enveloped virions (Fig 1C).
We next determined the average number of P-mCherry protein copies per particle by com-
paring the particle brightness of RABV P-mCherry and a pseudorabies virus (PRV; swine
αHV) recombinant expressing a capsid protein (pUL25)-mCherry fusion (S1A Fig). Because
pUL25 is incorporated in precisely 60 copies in αHV capsids [24], we could extrapolate the P-
mCherry protein copy number by comparing the fluorescence emission intensities between
virus recombinants [25] (S1B Fig). RABV P-mCherry nucleocapsids contained approximately
116 copies of P-mCherry protein on average (S1C Fig). Thus, RABV nucleocapsids incorpo-
rate sufficient copies of P-mCherry protein for effective visualization of single virus particles.
Sympathetic neurons are susceptible to RABV infection
We routinely model axonal invasion by neuroinvasive viruses using primary rodent sympa-
thetic superior cervical ganglia (SCG) of the autonomic nervous system [26]. SCG ganglia con-
tain a homogenous population of neurons that grow robust axons in the presence of NGF,
which enables reproducible and well-controlled axonal infections [27]. However, to our
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Fig 1. Construction of a CVS-N2c RABV recombinant for live-cell imaging in PNS neurons. (A) Genome schematics of the parental strain and P-mCherry-
expressing, spread-deficient RABV recombinant. (B) Protein composition of sucrose-purified RABV P-mCherry particles (lanes 1 and 3) using SDS-PAGE and
western blotting with anti-RABV P, G, N, or M. N2c mCherry particles (G-complemented N2cΔG expressing diffusible mCherry) are included for comparison
(lanes 2 and 4). Asterisk indicates P-mCherry fusion protein. (C) Pie chart shows the proportion of enveloped virions (dual colored; 888) to non-enveloped
nucleocapsids (red-only; 426) in the RABV P-mCherry stock (n = 1314 particles total). P-mCherry-positive particles (red) from purified supernatants were stained
with anti-RABV G and Alexa Fluor 488-conjugated 2˚ antibody (green) (scale bars = 10 μm) (see also S1 Fig). (D) Dissociated SCG were infected with RABV P-
mCherry (105 ffu) (red) and stained at 48 hpi with FITC-conjugated anti-RABV targeting the N protein (green). DAPI stains nuclei (blue). White arrow indicates a
cytoplasmic inclusion body (scale bar = 25μm).
https://doi.org/10.1371/journal.ppat.1007188.g001
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knowledge, only a single study has investigated RABV infection in SCG in vitro [28]. There-
fore, we first determined if SCG neurons are indeed susceptible to RABV infection. Dissoci-
ated SCG were infected with RABV P-mCherry and imaged for P-mCherry expression at 48
hours post infection (hpi). The P-mCherry signal was present in large punctae throughout the
cytoplasm of dissociated SCG cell bodies (Fig 1D). Fixed cells were stained with FITC-conju-
gated anti-RABV targeting RABV nucleoprotein (N). We observed near complete co-localiza-
tion between P-mCherry and N protein. Cytoplasmic inclusion bodies containing the RABV P
and N proteins are characteristic of rabies replication compartments, suggesting that SCG neu-
rons are susceptible and permissive to RABV infection in vitro.
RABV infects sympathetic neurons in tri-chambers via axonal infection
The tri-chamber compartmented neuron culture system separates axons from cell bodies by
two physical barriers. This system enables directional infections that mimic the natural route
of nervous system invasion, where virus particles enter axons and undergo retrograde-directed
transport toward distant cell bodies.
SCG are grown in tri-chambers as described previously [29] (Fig 2A). Briefly, SCG cell bod-
ies are dissociated and seeded in the S (soma) compartment. Cell bodies extend long axons
that penetrate beneath the two barriers of the M (methocel/middle) compartment and into the
N (neurite) compartment. To visualize and count the cell bodies that extend axons through to
the N compartment, a green lipophilic dye (DiO) is added to the N compartment axons. This
dye diffuses along axons to label the connected cell bodies in green (Fig 2A and 2B).
We first determined how many RABV particles must be added to axons to establish an
infection in the cell bodies in the S compartment. We measured RABV infection based on
viral protein expression in the cell bodies. Specifically, we used fluorescence microscopy to
detect expression of the P-mCherry fusion protein. We infected axons with 100, 101, 102, 103,
104, 105, or 106 focus forming units (ffu) of RABV P-mCherry and calculated the percentage
of connected cell bodies that became infected based on P-mCherry expression. No P-
mCherry expression was observed in the cell bodies when axons were infected with 100 ffu.
When axons were infected with 101, 102, and 103 ffu, P-mCherry was expressed in a small
percentage of the connected cell bodies (0.01 ± 0.03%, 0.2 ± 0.2%, and 2.4 ± 1.3%, respec-
tively) (Fig 2C). When axons were infected with 104, 105, and 106 ffu, P-mCherry was
expressed in 25.2 ± 8.4%, 84.8 ± 4.7%, and 84.9 ± 2.0% of the connected cell bodies, respec-
tively. In all conditions, the percentage of infected cell bodies did not increase after 72 hpi,
confirming that the virus is spread-deficient. Therefore, a specific threshold of particles
( 104 ffu) must be exceeded to establish an efficient retrograde RABV infection. The maxi-
mum cell body infection is reached when axons are infected with 105 ffu, above which, the
infection is saturated. All future axonal infection experiments were conducted using 105 ffu
of RABV P-mCherry.
To monitor the dynamics of retrograde RABV infection in SCG in tri-chambers, we calcu-
lated the percentage of infected cell bodies starting at 20 h and up to 168 h after axonal infec-
tion with 105 ffu of RABV P-mCherry. The percent of cell bodies expressing P-mCherry
increased significantly between 20 and 24 hpi (from 38.3 ± 10.3% to 56.0 ± 6.6%; p = 0.01) and
between 24 and 48 hpi (from 56.0 ± 6.6% to 79.2 ± 8.7%; p = 0.0006) (Fig 2D). The maximum
percent of infected cell bodies was observed at 48 hpi with no significant increase at 72 hpi
(84.0 ± 7.0%) or 168 hpi (86.7 ± 8.8%). To verify the P-mCherry fusion in infected cells, we col-
lected cell bodies at 72 h post axonal infection and used western blotting with anti-mCherry
antibody. We observed a major band at the expected size for the P-mCherry fusion protein
(~61 kDa) but no band for the unfused mCherry protein (~27 kDa) (Fig 2E). Thus, RABV
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Fig 2. RABV infects sympathetic neurons in tri-chambers via axonal infection. (A) Retrograde infection in tri-chambers (S, soma (left); M,
methocel (middle); N, neurite (right)). (B) Cell bodies in S at 24 h post RABV P-mCherry infection (105 ffu) in N. White arrow indicates an
infected cell body with axonal connection to N. White asterisks indicate etched grooves (scale bar = 500 μm). (C) Quantification of % infected
cell bodies at 72 hpi when axons were infected with different numbers of viral particles (100 ffu–106 ffu). (D) Quantification of % infected cell
bodies from 20 h to 168 h post axonal infection with 105 ffu. Black dots in (C) and (D) represent individual tri-chambers (from three (C) and
two (D) independent replicates). Horizontal lines and errors bars represent mean ± SD for each condition with p = 0.01, p = 0.0006,
p< 0.0001 using one-way ANOVA (ns = not significant). (E) Anti-mCherry western blot of protein lysate from S compartment cell
bodies at 72 h post axonal infection (105 ffu). Arrowhead indicates band for P-mCherry fusion protein (~60 kDa). Asterisk indicates expected
size of unfused mCherry protein (~27 kDa), which is not present in infected cells.
https://doi.org/10.1371/journal.ppat.1007188.g002
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enters SCG axons and moves retrograde to infect approximately half of the connected cell bod-
ies within 24 h. The infected cell bodies express the intact P-mCherry fusion protein.
Retrograde RABV infection is unaffected by axonal interferon treatment
We have shown previously that pre-exposure of SCG axons to either type I (IFNα/β) or type II
(IFNγ) interferon reduces the axonal transport of αHV particles but not lysotracker-positive
vesicles [8]. Because RABV and αHV particles use distinct axon entry/transport mechanisms
(in endosomes (RABV) vs. vesicle-independent (αHV)), we determined if exposing axon ter-
mini to these pro-inflammatory cytokines would also restrict retrograde infection by RABV.
Axons in the N compartment were pretreated with IFNβ or IFNγ for 24 h prior to infection
with RABV P-mCherry. At 5 hpi, DiO was added to the axon compartment to label the con-
nected cell bodies (Fig 2A). At 24 h post axonal infection, there was no significant difference
in P-mCherry expression in the cell bodies regardless of whether axons were pretreated with
IFNβ, IFNγ or untreated (Fig 3A). P-mCherry was expressed in 47.0 ± 5.3% of the connected
cell bodies in the control condition and in 50.8 ± 9.0% and 50.8 ± 9.9% of the connected cell
bodies in the IFNβ and IFNγ pretreated conditions, respectively (Fig 3B).
To verify that IFNβ and IFNγ were active, we added IFNβ or IFNγ directly on the cell bod-
ies in the S compartment 24 h prior to axonal infection. Consistent with previous reports of
interferon inhibiting RABV replication [30,31], we observed a statistically significant decrease
in P-mCherry expression in cell bodies that were directly pretreated with either IFNβ or IFNγ.
The percentage of infected cell bodies decreased from 47.0 ± 5.3% (untreated) to 33.4 ± 10.9%
(p = 0.0114) and 8.83 ± 6.8% (p< 0.0001) when cell bodies were exposed to IFNβ or IFNγ,
respectively (Fig 3B). IFNβ pretreatment of cell bodies did not completely abolish RABV infec-
tion, suggesting that RABV P-mCherry maintains its IFN antagonist activity [32,33].
As an additional control for IFN activity, we measured phosphorylation of STAT1 (signal
transducer and activator of transcription 1), a downstream effector of the IFN response. IFNβ
or IFNγ was added to the N compartment, and after a 24 h treatment, the N and S compart-
ments were lysed separately and analyzed by western blot. Consistent with previously pub-
lished results [8], axonal IFNβ treatment induced phosphorylation of STAT1 only in axons,
whereas axonal IFNγ treatment induced accumulation of phosphorylated STAT1 in the distant
cell bodies (S2 Fig).
Axonal interferon treatment does not alter retrograde axonal transport of
RABV particles
To confirm that axonal IFN exposure has no effect on retrograde RABV infection, we used
time-lapse video microscopy with high temporal resolution (> 10 frames/sec) to track the
number of RABV particles transported retrograde into the M compartment in the presence or
absence of IFNβ or IFNγ between 2–4 h post-axonal infection (Fig 4A). We first confirmed the
identity of the transported P-mCherry particles in M compartment axons by anti-RABV N
staining (S3 Fig). We then visualized and counted the tracks of moving RABV particles using
maximum intensity projections of each field of view (FOV) along the M compartment barrier
(Fig 4B). We constructed kymographs to visualize the displacement of individual RABV parti-
cles over time during 15 second movies (Fig 4C). In all treatment conditions, particles moved
with similar kinetics and relatively constant velocities. There was no significant difference in
the average number of particles moving retrograde per FOV across the untreated (5.4 ± 4.7
particles), IFNβ pretreated (4.7 ± 3.4 particles) and IFNγ pretreated (5.0 ± 4.2 particles) axons
(Fig 4D). Unlike the effect on αHV axonal infection, exposure of axons to IFNβ or IFNγ does
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Fig 3. Retrograde RABV infection is unaffected by axonal interferon treatment. (A) Cell bodies in S at 24 h post
RABV P-mCherry infection in N. IFNβ or IFNγ was added to N for 24 h prior to axonal infection (scale
bars = 250 μm). (B) Quantification of % infected cell bodies at 24 hpi (+/-) IFNβ or IFNγ in N or S. Black dots
represent individual tri-chambers (from three independent replicates). Horizontal lines and errors bars represent
mean ± SD for each condition with p = 0.0114, p< 0.0001 using one- way ANOVA (ns = not significant).
https://doi.org/10.1371/journal.ppat.1007188.g003
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not reduce retrograde RABV infection in the connected cell bodies nor does it alter axonal
transport dynamics of RABV particles.
Axonal emetine treatment blocks retrograde RABV infection
We previously reported that retrograde αHV infection requires local protein synthesis in
axons, and αHV transport is reduced by treatment of isolated axons with protein synthesis
inhibitors [7]. To determine if inhibition of axonal protein synthesis blocks retrograde RABV
infection, N compartment axons were pretreated with the protein synthesis inhibitor, emetine,
Fig 4. Axonal interferon treatment does not alter retrograde axonal transport of RABV particles. (A) Live particle tracking setup (see also S3 Fig). IFNβ or
IFNγ was added to N for 24 h prior to infection in N. (B) Motile RABV particle tracks (black lines) visualized by maximum intensity projections from each field of
view (FOV) along the M compartment barrier at 2–4 hpi in N (scale bars = 20 μm). One FOV is shown per condition. Blue boxes highlight tracks of particles that
moved retrograde for the entire duration of the 15 sec movie (163 frames). (C) For tracks in blue boxes, kymographs show the displacement of each particle over
time. Diagonal lines indicate particles moving retrograde. (D) Quantification of the number of RABV particles moving retrograde per FOV (+/-) IFNβ or IFNγ
pretreatment in N. Each open circle represents an individual FOV. Vertical lines and error bars represent the mean ± SD for each condition (ns = not significant
using one-way ANOVA). Total FOVs counted were 308 (no treatment), 297 (IFNβ), and 309 (IFNγ) across 3 independent replicate chambers per condition.
https://doi.org/10.1371/journal.ppat.1007188.g004
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1 h prior to RABV infection (see Fig 2A). Emetine-containing media was removed 5 hpi. We
observed a remarkable decrease in the percentage of P-mCherry-positive cell bodies in the
emetine-treated samples when compared to untreated samples, and this effect was dose-
dependent (Fig 5A and 5B; see also S4A Fig). At 24 hpi, the percentage of infected cell bodies
was 29.4 ± 8.5% in the untreated condition versus 14.0 ± 6.7%, 4.5 ± 2.0%, and 0.01 ± 0.02% in
the 10 μM, 50 μM, or 100 μM emetine-treatment conditions, respectively (S4A Fig).
In axons treated with 100 μM emetine, retrograde infection was essentially blocked at 24
hpi (Fig 5B). The percentage of infected cell bodies remained significantly decreased for 72 hpi
when compared to the control. However, a smaller proportion of cell bodies did become
infected at later time points. In the emetine treated condition, P-mCherry was expressed in
12 ± 9% of the connected cell bodies at 48 hpi (vs. 63.0 ± 11.3% in 48 hpi untreated), and
20 ± 12% of the connected cell bodies at 72 hpi (vs. 68.4 ± 9.1% in 72 hpi untreated).
We verified that the observed decrease in retrograde infection was due to local effects of
emetine on isolated axons and not due to diffusion of the drug to the connected cell bodies. N
compartment axons were pretreated with emetine, but in this case, S compartment cell bodies
were directly infected with RABV at 1 h post axonal emetine treatment. At 24 hpi, there was
no significant difference in the percentage of infected cell bodies between the control and eme-
tine-treated conditions (80.21 ± 12.5% and 83.14 ± 6.9%, respectively) (S4B Fig). Thus, when
emetine is added to the N compartment, it acts locally in axons to block retrograde RABV
infection in a dose-dependent manner.
To rule out the possibility that axonal emetine treatment has toxic effects, we first exam-
ined the morphology of axons and cell bodies at 24 h after axons had been treated with eme-
tine for 6 h. Regardless of whether axons were treated with 100 μM emetine or untreated, the
axons and cell bodies were intact and healthy with no apparent toxicity (e.g. no varicosity
formation or blebbing) (S5A Fig). We then used SYTOX, a nucleic acid stain that is imper-
meant to live cells, to further analyze the percentage of live versus dead cell bodies after
axons were treated with 100 μM emetine for 6 h. After a 6 h treatment, we counted a similar
percentage of dead cell bodies in the emetine-treated condition (3.9% dead cells) versus the
untreated (3.2% dead cells) (S5B and S5C Fig). We also imaged the cells at 24 h after a 6 h
treatment with emetine in the N compartment (i.e. emetine was washed out at 6 h) and
found no increase in cell death after 24 h (3.5% dead cells). By contrast, when emetine was
added directly to the cell bodies in the S compartment, we observed a substantial increase in
the percentage of dead cells after a 6 h treatment (14.4% dead cells) and a longer 24 h treat-
ment (46.5% dead cells). Therefore, exposing isolated axons to 100 μM emetine for 6 h causes
no apparent toxicity.
Emetine blocks retrograde RABV infection by a mechanism that does not
depend on protein synthesis inhibition
Because emetine is a translation elongation inhibitor, we hypothesized that the early steps of
RABV entry and/or retrograde transport in axons require local, axonal protein synthesis to
proceed efficiently. To test this hypothesis, we exposed axons to two other well-known protein
synthesis inhibitors and measured the extent of retrograde RABV infection. Axons in the N
compartment were treated with either the translation elongation inhibitor, cycloheximide
(CHX) or the polypeptide chain terminator, puromycin, 1 h before axonal infection. Unex-
pectedly, neither of these inhibitors blocked retrograde RABV infection. In the CHX- and
puromycin-treated conditions, 24.6 ± 10.9% and 28.5 ± 6.9% of the connected cell bodies
became infected compared to 30.4 ± 8.4% in the control at 24 hpi (Fig 5C). By contrast, eme-
tine treatment reduced the percentage of infected cell bodies to 0.4 ± 0.5%.
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Fig 5. Axonal emetine treatment blocks retrograde RABV infection by a mechanism that does not depend on protein synthesis inhibition. (A) Cell bodies in
the S compartment at 24 h post RABV P-mCherry infection in N. Emetine (100 μM) was added to N, 1 h prior to axonal infection and washed out at 5 hpi (scale
bar = 250 μm). (B) Quantification of % infected cell bodies at 24, 48, and 72 hpi (+/-) 100 μM emetine in N. (C) Quantification of % infected cell bodies at 24 hpi
(+/-) 100 μM emetine, 100 μg/ml CHX, or 10 μg/ml puromycin added to N or S, 1 h prior to infection in N. Inhibitors were washed out at 5 hpi. Black dots in (B)
and (C) represent individual tri-chambers (from four (B) and three (C) independent replicates). Horizontal lines and errors bars represent mean ± SD for each
condition with p< 0.0001 using two-way (B) or one-way (C) ANOVA (ns = not significant). (D) Levels of phosphorylated eIF2α (P-eIF2α) in dissociated SCG
(+/-) 100 μM emetine, 100 μg/ml CHX or 10 μg/ml puromycin (6 h post treatment).
https://doi.org/10.1371/journal.ppat.1007188.g005
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To confirm that the protein synthesis inhibitors were active at the concentrations tested, we
added emetine, CHX or puromycin to cell bodies in the S compartment and infected the N
compartment with RABV 1 h post inhibitor treatment. Retrograde RABV infection was
completely abolished when each of these drugs was added directly to the S compartment, sug-
gesting that CHX and puromycin actively block viral replication in cell bodies despite having
no local effect in axons (Fig 5C).
We further confirmed translation inhibition by assessing the phosphorylation state of
eIF2α (eukaryotic initiation factor 2 alpha) in dissociated SCG treated with emetine, CHX, or
puromycin for 6 h. The level of phosphorylated eIF2α increased in each drug-treated condition
as compared to the non-treated condition (Fig 5D). Because retrograde RABV infection is
blocked exclusively by emetine but not by other protein synthesis inhibitors, we conclude that
emetine inhibits axonal infection by an alternative mechanism that is independent of cytosolic
protein synthesis inhibition.
Emetine limits axonal transport of RABV particles but does not restrict
transport of Rab5- or Rab7-positive vesicles
We used video microscopy to determine if emetine blocks retrograde infection by limiting the
number of RABV particles transported toward the cell bodies. We infected N compartment
axons with RABV P-mCherry in the presence or absence of emetine and imaged along the M
compartment barrier between 2 and 4 hpi to count the number of particles moving toward the
cell bodies (Fig 6A). In the presence of emetine, we observed a significant decrease in the num-
ber of particles moving retrograde per FOV in the M compartment. We counted 5.0 ± 3.9
moving particles/FOV in the untreated axons versus 1.5 ± 0.9 in the emetine pretreated axons
(p< 0.0001) (Fig 6B).
To determine whether emetine inhibits global axonal transport, we tested emetine’s effect
on the transport of vesicles containing Rab5 (Ras-related protein 5) or Rab7, which localize to
early and late endosomes, respectively [34]. Cell bodies in the S compartment were transduced
with adenoviruses expressing either Venus-Rab5 or Venus-Rab7 fusion protein (Fig 6C). At 4
days post transduction, emetine was added to the N compartment (in the absence of RABV
infection), and axons in the N compartment were imaged at 2–4 h post treatment. We calcu-
lated the percentage of Rab5 or Rab7 particles moving per axon and found no significant
difference between the emetine pretreated and untreated axons (Fig 6D). The percent of
Rab5-positive vesicles moving per axon was 41 ± 13% in the control versus 42 ± 16% in the
emetine treated axons. For Rab7, the percent of vesicles moving per axon was 52 ± 12% (con-
trol) versus 45 ± 13% (emetine). Thus, emetine specifically affects RABV and does not reduce
transport of cellular vesicles.
Emetine acts after RABV entry to reduce the velocity and transport
distance of virus particles moving retrograde in axons
We next determined whether emetine affects axon entry of RABV particles. If emetine’s pri-
mary effect was on RABV entry, we expected that retrograde infection would be unaltered if
emetine was added to the N compartment after viral entry occurred. To define the window of
time for the majority of RABV entry events to occur, we measured how long virus inoculum
must be in contact with axons to establish an efficient retrograde infection in the cell bodies
within 24 h. Axons in the N compartment were incubated with RABV P-mCherry inoculum
for 1 min, 10 min, 30 min, 60 min, 120 min, or 300 min (S6A Fig). The percentage of infected
cell bodies was 0% after 1 min, 3.1 ± 1.1% after 10 min, 14.0 ± 5.2% after 30 min, 25.7 ± 4.4%
after 60 min, 25.1 ± 1.1% after 120 min, and 28.6 ± 4.7% after 300 min (S6B Fig). Incubations
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longer than 60 min did not significantly increase the percentage of infected cells. Therefore, 60
min provides a suitable time window for the majority of axon entry events to occur.
We found that retrograde RABV infection in the cell bodies was almost completely abolished
regardless of whether emetine was added to axons prior to or after infection. When emetine
was added to axons 1 h after infection, we still observed a significant decrease in the percentage
of infected cell bodies from 32.3 ± 12.9% (untreated) to 2 ± 1% (p< 0.0001) (Fig 7A). Findings
suggest that the primary antiviral effect of emetine is not on RABV entry into axons.
Fig 6. Emetine restricts axonal transport of RABV particles but does not limit transport of Rab5- or Rab7-positive vesicles. (A) 100 μM Emetine was added to
N, 1 h prior to RABV P-mCherry infection in N. (B) Quantification of the number of RABV particles moving retrograde per FOV (+/-) emetine pretreatment in N.
Open circles represent individual FOVs along the M compartment barrier. Vertical lines and error bars represent the mean ± SD for each condition with
p< 0.0001 using unpaired t-test. Total FOVs counted were 224 (no treatment) and 166 (emetine) across 3 independent replicate chambers per condition. (C)
S compartment cell bodies were transduced with adenoviruses expressing either Venus-Rab5 or Venus-Rab7 for 4 days. (D) Quantification of % moving Rab5 or
Rab7 particles per axon (+/-) 100 μM emetine. Each dot represents one axon in the N compartment. A minimum of 22 axons were imaged per condition.
Horizontal lines and error bars represent the mean ± SD for each condition (ns = not significant using two-way ANOVA).
https://doi.org/10.1371/journal.ppat.1007188.g006
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Fig 7. Emetine acts after RABV entry to reduce the velocity and transport distance of virus particles moving retrograde in axons. (A)
Quantification of % infected cell bodies at 24 hpi (+/-) 100 μM emetine added to N either 1 h pre or 1 h post infection. Black dots represent individual
tri-chambers (from two independent replicates). Horizontal lines and errors bars represent mean ± SD for each condition with p< 0.0001 using
one-way ANOVA (ns = not significant). (B) Motile RABV particle tracks (black lines) visualized by maximum intensity projections from each FOV
along the M compartment barrier at 2–4 hpi in N (scale bars = 20 μm). (C) For tracks in blue boxes, kymographs show the displacement of particles
over time during the 15 sec movie (163 frames). The slope indicates the velocity of particle movement, where a vertical line has a slope of zero and
indicates particle stalling. (D) Distribution of RABV particle velocity (μm/sec) across a population of retrograde moving RABV particles in the
untreated (red; n = 10300 constant velocity segments from 1116 events) or emetine-pretreated (blue; n = 3363 constant velocity segments from 338
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We next determined if emetine alters the dynamics of RABV transport by modifying the
velocity or transport distance of moving particles. We visualized tracks of RABV particles
moving in the retrograde direction by maximum intensity projections of each FOV in the M
compartment at 2–4 h after N compartment infection (Fig 7B). From individual tracks, we
constructed kymographs to characterize the motion of particles during 15 second movies (163
frames) (Fig 7C). The velocity of particle movement is represented by the slope of the track in
the kymograph. In the emetine-treated condition, kymograph analysis indicated periods of
decreased slope (closer to zero) with more frequent stalling as compared to the control track
(Fig 7C).
To understand how emetine affects the velocity of moving RABV particles across the entire
population, we parsed individual particle tracks from M compartment movies into segments
of constant velocity and calculated the average instantaneous velocity for each segment. RABV
particles moved slower in the emetine pretreated condition (0.76 ± 0.02 μm/s) versus the con-
trol condition (1.0 ± 0.01 μm/s) (Fig 7D). To determine how far RABV particles traveled in
the retrograde direction in the absence and presence of emetine, we measured the length
of each particle track. RABV particles traveled shorter distances in the emetine condition
(12.5 ± 0.6 μm) versus the control (18.3 ± 0.4 μm) (Fig 7E). Taken together, emetine treatment
significantly reduces the number of RABV particles transported toward the cell bodies. For the
minority of particles that still move in the retrograde direction in the presence of emetine, they
move with altered transport dynamics, including slower velocities and shorter distances.
Discussion
Nervous system infection is usually a dead end for many viruses; the host dies and viral trans-
mission is terminated. Yet viruses of the Rhabdoviridae family and the alpha herpesvirinae sub-
family, have evolved strategies that exploit neuronal biology to efficiently infect the nervous
system and still preserve host-to-host transmission. Recent work has revealed that RABV
hijacks the neurotrophin signaling pathway, and αHVs repurpose the axon damage response
to invade peripheral nervous system axons [7,16]. Both strategies achieve a common goal: the
efficient dynein-mediated retrograde transport of viral particles from axon terminus to cell
body where viral replication ensues. Due to the extreme spatial separation of axons from cell
bodies, the axon is a neuronal sub-compartment that senses external stimuli and mounts inde-
pendent local responses. An outstanding question is do such axonal responses regulate or limit
axonal infection by two distinct neuroinvasive viruses?
Previous studies have investigated RABV axonal transport using attenuated vaccine strains
(SAD B19) or RABV G-pseudotyped vesicular stomatitis virus and lentivirus [11,12,16,18,35].
In this study, we extend the current understanding of RABV axon transport dynamics by use
of a neurovirulent CVS-N2c-derived RABV P-mCherry-expressing recombinant. We charac-
terize RABV infection in SCG sympathetic neurons grown in compartmented neuronal cul-
tures, in which the physical separation of cell bodies enables selective infection or treatment of
events) condition. Events were pooled from three independent replicates. Y axis indicates the frequency for each velocity on the x-axis. Positive and
negative values indicate retrograde and anterograde directed motility, respectively. v = the mean velocity ± standard error of the mean (SEM) (E)
Distribution of RABV particle track length for particles moving retrograde in the untreated (red; n = 637 particles) or emetine-pretreated (blue;
n = 231 particles) conditions. Y axis indicates the frequency for each track length on the x-axis. x = the mean particle track length (± SEM). Lines on
the histograms in (D) and (E) are cubic spline curves. (F) Our suggested model summarizing the effect of emetine on post-entry retrograde transport
of RABV virions. RABV particles first attach to the cell surface receptors (step 1) to initiate entry through endocytosis (step 2). Step 1 and 2 induce
signaling pathways including JNK, ERK, RhoA, stathmin and NfkB in axons (step 3). RABV-carrying endosomes must recruit dynein motors and
adapters (step 4) to facilitate efficient retrograde transport on microtubules (step 5). We propose that emetine does not block step 1 or 2, but it
interferes with step 5 by possibly inhibiting step 3 and/or 4.
https://doi.org/10.1371/journal.ppat.1007188.g007
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isolated axons. Although somatic motor neurons are predominantly infected by RABV in vivo
[36,37], the autonomic motor neurons of the SCG are a homogenous population that provides
a good model of the early steps of neuroninvasion due to highly reproducible and quantifiable
axonal infections. To date, sensory dorsal root ganglia (DRG) or ventral spinal cord neurons
have been used for RABV axonal transport studies. However, unlike SCG, spinal cord neurons
exhibit limited axonal projections in compartmented cultures [12], and DRG are heterogenous
with subpopulations of unmyelinated neurons that display resistance to RABV infection [38].
We established an ex vivo model of RABV infection in compartmented SCG neurons to facili-
tate high resolution imaging of RABV axon transport as well as concurrent biochemical analy-
ses of RABV-infected axons.
Using this system, we showed that SCG axons do not regulate RABV and αHV invasion in
the same way. We previously reported that treatment of axons with either type I IFN (IFNβ) or
type II IFN (IFNγ) was sufficient to limit retrograde αHV infection by reducing the percentage
of moving αHV particles by at least 50%. Exposure of axons to IFNβ induced a strictly local
axonal response where STAT1 was phosphorylated and retained in axons. Whereas, exposure
of axons to IFNγ induced a long distance signaling response where phosphorylated STAT1
was present in the connected cell bodies but not the axons. Importantly, axonal IFN exposure
had no effect on the transport of cellular lysosomes, suggesting that vesicular transport was
unaffected [8].
As expected, proinflammatory cytokine pretreatment of neuronal cell bodies moderately
suppressed RABV infection in this compartmented system. However, exposure of isolated
axons to IFNβ or IFNγ, had no effect on RABV neuroinvasion. Why does axonal IFN exposure
restrict αHV transport but have no effect on RABV? The most apparent explanation is that
RABV is shielded from the axonal inflammatory response due to endosome-mediated trans-
port. Previous studies in hippocampal neurons [39], motor neurons [35], and dorsal root gan-
glia (DRG) neurons [12,16] showed that clathrin-mediated endocytosis is the primary entry
mechanism for RABV particles. In contrast, the primary entry mechanism for αHV is mem-
brane fusion followed by release of non-enveloped viral capsids and tegument proteins into
the axoplasm [40]. αHV particles interact directly with dynein and are not transported inside
vesicles [41]. As a result, αHV are likely to be more overtly susceptible to IFN-induced axonal
responses.
The contrasting effects of axonal IFN exposure on RABV and αHV likely reflect differences
in how these viruses evolved with their hosts. Unlike RABV which is 100% lethal after infection
of most mammals, αHV establish a lifelong latent infection in the PNS ganglia of the host.
Given the importance of latency establishment for αHV persistence, it is possible that αHV
evolved to exploit the innate immune response to bias the infection mode toward latency.
Interestingly, axonal IFN exposure reduces the number of αHV particles transported toward
the cell bodies, which leads to silencing of herpesviral genomes in the neuronal nuclei [42,43].
Such exposure of isolated axons to IFN is biologically relevant for αHV because the initial rep-
lication in mucosal epithelia triggers the production and release of proinflammatory cytokines
that bathe the innervating axon termini. Perhaps RABV encounters a different inflammatory
milieu than αHV in its natural host, giving rise to distinct evolutionary pressures that affect
how these viruses respond to innate defenses.
Previous studies have shown that axons respond not only to inflammatory cytokine expo-
sure, but also to damage, axon guidance cues, and αHV infection by local translation of spe-
cific pools of mRNAs [5,7,44]. However, axonal RABV infection did not induce detectable
new protein synthesis, and there was no effect on RABV infection when we treated axons with
cycloheximide or puromycin. By contrast, we found that emetine dramatically blocked retro-
grade RABV infection in a dose-dependent manner. We first observed that axonal emetine
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pretreatment strongly limited infection in the connected cell bodies, reducing the percentage
of infected cells from 30% to less than 0.5%. Importantly, retrograde infection was still blocked
when emetine was added to axons 1 h after infection, suggesting that emetine functions after
RABV particles enter axons. Furthermore, axonal emetine pretreatment caused a 70% decrease
in the number of particles moving in the retrograde direction into the middle compartment.
The few particles that still moved in the presence of emetine, moved an average of 25% slower
and traveled approximately 5.5 μm less than particles in untreated samples. The effect of eme-
tine is not due to a global inhibition of axon transport because in the absence of RABV infec-
tion, emetine does not limit the proportion of moving Rab5- or Rab7-positive vesicles in
axons. Emetine was the only protein synthesis inhibitor that blocked infection, suggesting that
protein synthesis inhibition is not the primary mechanism by which emetine inhibits retro-
grade RABV infection.
A number of groups have recently reported new antiviral roles for emetine. Emetine was
shown to inhibit viral nucleic acid synthesis in cultured cells infected with the RNA viruses,
PPRV (peste des petits ruminants virus) and NDV (Newcastle disease virus), or the DNA
viruses, BPXV (buffalo poxvirus) or BHV-1 (bovine herpes virus). Entry of NDV-1 and BHV-
1 was also inhibited by emetine [45]. Furthermore, emetine inhibited human cytomegalovirus
(HCMV) replication by disrupting the HCMV-induced interaction between p53 and the
E3-ubiquitin ligase, MDM2. Importantly, this effect was not attributed to protein synthesis
inhibition because translation was not inhibited at the concentrations used [46].
Recent reports, particularly in the cancer literature, have introduced emetine as an impor-
tant modulator of cellular signaling pathways. In a screen of ~2800 clinically approved drugs,
emetine was found to block NF-кB (nuclear factor-kappa B) activation via inhibition of IкBα
phosphorylation in human cervical cancer cell lines [47]. A separate study showed that eme-
tine promotes splicing of Bcl-x to a pro-apoptotic variant in several tumor cell lines, and this
action is dependent on the emetine-induced activation of protein phosphatase 1 (PP1). Nota-
bly, the authors concluded that this effect of emetine on splicing was not likely to be dependent
on protein synthesis inhibition because several other protein synthesis inhibitors did not have
analogous effects [48]. In human non-small-cell lung cancer cells (NSCLC), emetine treatment
inhibited NSCLC migration and invasion via selective down-regulation of matrix metallopro-
teases that degrade the extracellular matrix. The mechanism underlying this effect of emetine
was an increased phosphorylation of p38 MAPK (mitogen-activated protein kinase) and
decreased phosphorylation of ERK (extracellular signaling regulated kinase) [49]. Interest-
ingly, ERK1/2-mediated phosphorylation of the dynein intermediate chain was reported to
enhance dynein recruitment to signaling endosomes and to promote retrograde axonal trans-
port of these organelles [50].
We propose that emetine alters local signaling events in axons that are triggered by RABV
infection and required for efficient retrograde transport of RABV (Fig 7F). Gluska et al. 2014
recently reported that retrograde transport of RABV was faster than transport of nerve growth
factor (NGF), even though RABV exploited the endogenous NGF entry/transport route medi-
ated by p75 neurotrophin receptor (p75NTR). The authors suggest that the increased RABV
transport velocity is due either to recruitment of extra motors via receptor clustering at the
membrane or to alteration of intra-axonal signaling pathways (e.g. JNK, RhoA, Stathmin,
NfкB) downstream of receptor binding. We observed that emetine had no effect on virion
entry but decreased the transport velocity of retrograde moving RABV particles. Perhaps an
emetine-induced modulation of axonal signaling events prevents effective cargo-motor load-
ing or motor recruitment to the abnormally large RABV-containing endosomes (Fig 7F).
RABV-induced axonal signaling events and the effects of emetine on axonal signaling are cur-
rently under investigation.
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In summary, we show that axons have unique responses to two different viral infections.
Unlike what was previously reported for αHV, axonal protein synthesis is not required for
RABV neuroinvasion, and RABV transport is not hindered by exposure of axons to interferon.
Although both RABV and αHV repurpose the existing axonal transport machinery to establish
efficient nervous system infection, the regulation of this repurposing is distinct between these
two viruses. Furthermore, we show that exposure of axons to emetine efficiently blocks RABV
infection in the distant cell bodies. Although we have not fully elucidated the mechanism, to
our knowledge, this is the first study to show antiviral effects of emetine against RABV infec-
tion. These findings extend our current understanding of how viral neuroinvasion by two dis-
tinct viruses is regulated and point toward a novel role for emetine as an inhibitory modulator
of RABV axonal transport.
Materials and methods
Animals
Timed-pregnancy Sprague-Dawley rats (Rattus norvegicus) were obtained from Hilltop Labs
Inc. (Scottsdale, PA). E17 rat embryos were harvested for isolation of superior cervical ganglia
(SCG).
Primary superior cervical ganglia culture
SCG neurons were cultured in tri-chambers as described previously [26]. Briefly, SCG were
trypsin-digested, mechanically dissociated, and seeded in the S (soma) compartment of the tri-
chamber. Neurons extend axons beneath two physical barriers through the M (methocel/mid-
dle) compartment and into the N (neurite) compartment. Primary neurons were maintained
in Neurobasal media (ThermoFisher; 21103049) + 50X B-27 supplement (ThermoFisher;
17504044) + 100X Penicillin-Streptomycin-Glutamine (ThermoFisher; 10378016) + 80 ng/ml
NGF (ThermoFisher; 13257019) with media change every 5–7 days as needed. Neurons were
grown at 37˚C, 5% CO2 for 3–4 weeks prior to infection or drug treatment.
Cell lines and virus strains
Neuro2A (N2a) mouse neuroblastoma cells (American Type Culture Collection (ATCC)),
N2c G expressing N2a cells (NG cells) (Matthias Schnell Lab), and pig kidney epithelial cells
(PK15) (ATCC) were grown at 37˚C, 5% CO2 and maintained in DMEM + 10% FBS + 1%
Penicillin-Streptomycin (PS). RABV P-mCherry was recovered and propagated on N2c G-
expressing N2a cells. PRV recombinants mCherry-UL35 (960) and UL25-mCherry were prop-
agated on PK15 cells. When cell lines were infected with virus, FBS was reduced to 2% in the
infection media. Virus strains used in this study include RABV N2cΔG P-mCherry (described
below), PRV mCherry-UL35 (PRV 960) [51], and PRV UL25-mCherry [25].
Antibodies and chemicals
Fluorescein isothiocyanate (FITC)-conjugated anti-Rabies monoclonal globulin recognizing
the RABV N protein (FUJIREBIO Diagnostics, Inc. Malvern, PA; 800–092) was used at dilu-
tions of 1:200 for immunofluorescence (IF) and 1:1000 for western blot (WB). Anti-Rabies
virus glycoprotein antibody [1C5] (Abcam; ab82460) was used at 1:100 for IF. Rabbit poly-
clonal anti-RABV N (raised against purified ribonucleoprotein particles) was made by the
Schnell Lab and used at 1:1000 for WB. Monoclonal anti-RABV P antibody was a gift from
Danielle Blondel [52] and used at 1 μg/ml for WB. Polyclonal anti-RABV M (raised against a
SLQTQRSEEDKDSSL peptide from the C-terminus of M) was made by the Schnell Lab and
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used at 1:2000 for WB. Anti-RABV G for WB was a mixture of 4 human monoclonal antibod-
ies (4C12, 10H5, 8C5, 4H3) used at 1 μg/ml each. This was a gift from Scott Dessain at Lanke-
nau Institute of Medical Research. DAPI (4’,6-diamidino-2-phenylindole) stain was used at
1:1000 for IF. Alexa Fluor 488-conjugated goat anti-mouse IgG (H+L) secondary antibody
(Thermo Fisher; R37120) was used at 1:1000 dilution for IF. Anti-phosphorylated STAT1
(Cell Signaling Technology; 7649S) and anti-phosphorylated eIF2α (CST; 9721S) were used at
1:1000 for WB. Anti-β-Actin (Sigma; A1978) was used at 1:10,000 for WB. Horseradish peroxi-
dase-conjugated anti-mouse and anti-rabbit secondary antibodies (KPL; 31430 and 65–6120)
were used at 1:10,000 for WB.
Emetine dihydrochloride hydrate (Sigma Aldrich; 45160) was used at 100 μM (dissolved
in water) unless otherwise specified. Cycloheximide (CHX) (Sigma Aldrich; C7698) was
used at 100 μg/ml (dissolved in DMSO), and Puromycin (Invivogen; ant-pr) was used at
10 μg/ml (dissolved in DMSO). Emetine, CHX, or Puromycin were added 1 h prior to infec-
tion unless otherwise specified. For the untreated/ no treatment controls, the appropriate
solvent (water or DMSO) was added 1 h prior to infection unless other timing is specified.
Recombinant rat IFN-gamma protein (R&D Systems; 585-IF-100) and recombinant rat IFN-
beta (PBL Assay Science; 13400–1) were used at 500 U/ml (retrograde infection) or 1000 U/
ml (particle tracking). IFN treatment was initiated 24 h prior to infection. SYTOX Green
Nucleic Acid Stain (Thermo Fisher; S7020) was used at 5 nM for 10 min to label dead cells.
Fluorescent lipophilic dyes (DiO Green—Thermo Fisher; D275 and DiI Red—Thermo
Fisher; D282) were used at 1:1000 dilution to label cell bodies with axonal connection to the
N compartment.
Cloning a full-length cDNA of the recombinant N2cΔG P-mCherry genome
The RABV recombinant was derived from the highly neuroinvasive and neurotropic CVS-N2c
parental strain [21]. PCR primers were designed to amplify 3 DNA fragments: 1) RABV P, 2)
mCherry, and 3) RABV M with the intergenic region (IGR) after M, including an XmaI
restriction site. Primers were designed to facilitate insertion of DNA fragments into a
pCAGGS mammalian expression vector [53] in the following order: P, mCherry, M-IGR. The
following primers were used for PCR amplification:
N2c P: 5’-TTGGCAAAGAATTCGTCTCCGTACGACCATGAGCAAGATCTTTGTTA-3’
(fwd) and 5’-GAGCCGTCGCCGGAGCAGGATGTATAGCGATTC-3’ (rev);
mCherry: 5’-TACATCCTGCTCCGGCGACGGCTCTGGCATGGTGAGCAAGGGCGAG-3’
(fwd) and 5’-GAAAACTCGGTTACTTGTACAGCTCGTCCATG-3’ (rev);
N2c M-IGR: 5’-GTACAAGTAACCGAGTTTTCGAACTCAGTC-3’ (fwd) and 5’-GGGAAA
AAGATCTCGTCTCGCTAGCCTTCCCGGGGTCTTTTGAG-3’ (rev)
PCR products contained 15–40 bp of overlapping ends to facilitate fragment assembly. The
stop codon of P was mutated, and mCherry was fused to the C-terminus with a 5 amino acid
spacer sequence (GGG GAC GGC TCT GGC) inserted between the end of P and the start
of mCherry. PCR products were ligated into pCAGGS vectors using NEBuilder HiFi DNA
Assembly Cloning Kit (New England Biolabs; E5520S) following the recommended protocol
for assembly of DNA inserts into linear vectors. Briefly, the digested pCAGGS vector and the 3
PCR products were added to the HiFi DNA Assembly master mix in equimolar amounts (0.1
pmol/fragment) and incubated at 50˚C for 1 h. The ligation product was transformed into
NEB5α competent cells (NEB; C29871) following the manufacturer’s protocol, and minipreps
were prepared from single colonies. P-mCherry-M-IGR inserts were verified by restriction
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digest and DNA sequencing. P-mCherry expression was confirmed by fluorescence micros-
copy after transient transfection of the mammalian expression vector into N2a cells.
Verified inserts were digested out of the pCAGGS subcloning vector by cutting at the SpeI
site (C-terminus of P) and XmaI cloning site (flanking the 5’end of the glycoprotein gene),
and inserts were gel purified. The P-mCherry-M-IGR insert was ligated into the SpeI/XmaI-
digested N2c RABV genomic cDNA using T4 ligase (NEB; M0202S) overnight at room tem-
perature (RT). Ligated genomes were transformed into NEB5α cells, and single colonies were
picked for mini preps.
For RABVΔG, N2c RABV genomic cDNA was digested with SpeI and NheI (cloning site
flanking the 3’-end of the glycoprotein gene) to remove the genomic region from the C-termi-
nus of P to the end of the G gene. P-mCherry-M-IGR was digested out of the pCAGGS expres-
sion vector and re-ligated into the SpeI/NheI-digested N2c genomic cDNA. P-mCherry
insertion and G deletion were confirmed by restriction digest, and maxi preps were produced
from verified clones prior to virus recovery.
Recovery of recombinant N2c P-mCherry RABV and production of virus
stocks
The RABV recombinant was recovered on a complementing cell line expressing N2c G (NG
cells). The cells were made by transfecting N2a cells with plasmid vectors pTET-off (Clontech;
631017) and pTRE2Hyg (Clontech; 631014) containing the N2c glycoprotein gene. Clones
were selected with Geneticin and Hygromycin. Resistant clones were cultured in the absence
of doxycycline and screened by immunofluorescence staining with polyclonal antibody against
the RABV glycoprotein. Two clones that stained positive for RABV-G were selected (NG7 and
NG13) for setting up virus recovery and for large scale virus growth. Briefly, NG13 cells in 6
well dishes were transfected with 1.7 μg of full length genomic cDNA plus 2.5 μg of a mix of
pTIT-N, pTIT-P, pTIT-L, and pCAGGS-T7 combined in a 4:2:1:2 ratio, respectively. Plasmids
(pTIT) expressing the SAD B19 N, P, and L proteins were provided by Matthias Schnell [23].
The DNA transfection reagent, X-tremeGENE 9 (Roche; 06365809001) was used following the
recommended protocol. Following overnight incubation at 34˚C, the transfection reagent was
replaced with fresh infection media (DMEM +2% FBS + 1% PS). Transfected cells were pas-
saged once in 6 well dishes and then transferred to T-175cm2 flasks for the remainder of the
virus recovery period. The cells were kept at 34˚C for the duration of virus recovery and pas-
saged as needed with media change every 4 days.
Red fluorescent foci were visible as early as 8 days post transfection, and all cells expressed
P-mCherry by approximately 21 days post transfection. Supernatants were collected for virus
stocks at days 21, 24, and 28 post transfection. Supernatants were spun for 20 min at 3000 rpm
(4˚C) to pellet cell debris. Supernatants were filtered through 0.45 μm filters and concentrated
using Amicon Ultra -15 Centrifugal Filter Units (100KDa NMWL) (Millipore; Z740210). Con-
centrator units were spun for 20 min at< 4000 x g. Concentrated virus stocks were kept at
4˚C for immediate use or -80˚C for long term storage. Each virus stock was titered in triplicate
on N2a cells to determine the concentration (ffu/ml).
Viral particle purification
Concentrated virus stocks were overlaid on a 20% sucrose cushion in either 13.2 ml (Beckman
Coulter; 344059) or 38 ml (Beckman Coulter; 344058) thin wall, ultra-clear tubes. Tubes were
spun in a Beckman Coulter ultracentrifuge at 25,000 rpm for 1.5 h using the either the SW 41
Ti (13.2 ml tubes) or SW 32 Ti (38 ml tubes) swinging bucket rotor (107,000 x g). The superna-
tant was aspirated, the remaining liquid decanted, and the tubes were spun upside down in 50
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ml conical tubes to remove any residual liquid. Pellets were resuspended in PBS at 4˚C over-
night. 6% sucrose was added for cryopreservation.
Construction of adenoviral vectors
Adenoviral vectors were constructed by Gateway recombination into pAd/CMV/V5-DEST
vectors (Invitrogen; V49320). GFP was fused to the N-terminus of Rab5 or Rab7 as described
previously [54].
Western blotting
Dissociated SCG neurons or cell bodies from the S compartments were lysed in RIPA light
buffer (50 mM Tris-HCL, pH 8.0; 150 mM NaCl; 5mM EDTA; 1% (v/v) NP40; 0.1% (w/v)
SDS; 0.1% (v/v) Triton X-100) supplemented with 1 mM DTT and protease inhibitor cocktail
(Sigma Aldrich; P1860). Lysates were incubated on ice for 20 min and centrifuged at 10,000
rpm (4˚C) for 5 min. Supernatants were mixed with 5x laemmli buffer and heated for 10 min
at 90˚C. Axons from N compartments were directly lysed in 2x laemmli and heated. Proteins
were separated by SDS-PAGE on 4–12% NuPAGE Bis/Tris gels. Proteins were transferred
to nitrocellulose membranes (GE Healthcare; 45-004-002) using a Trans-Blot SD semi-dry
transfer cell (Bio-Rad). Membranes were blocked in 5% non-fat dry milk powder in PBS-T
(PBS-Tween, 0.1%) for 1 h at RT. Primary antibody was diluted in 1% milk powder in PBS-T.
Membranes were incubated with primary antibody overnight at 4˚C followed by PBS-T washes
(3 x 10 min). Horseradish peroxidase-conjugated anti-mouse and anti-rabbit secondary anti-
bodies (KPL) were diluted in 1% milk powder in PBS-T. Secondary antibody was added to the
membrane for 1 h at RT followed by three PBS-T washes. Chemiluminescent substrate, Super-
signal West Pico or West Dura (Pierce), was added to the membrane for 5 min. Protein bands
were visualized by exposing the blot on HyBlot CL autoradiography film (Denville scientific;
E3018). For detection of viral proteins in sucrose purified particles, proteins were separated by
SDS-PAGE on 10% polyacrylamide Tris/Glycine gels. Primary anti-RABV antibodies were
diluted in 10% BSA, and secondary antibodies were diluted in PBS-T + 5% milk powder.
Immunofluorescence staining
For immunofluorescence staining of P-mCherry-positive RABV particles, supernatants were
collected from G-expressing N2A cells (NG cells) at 7 d post RABV P-mCherry infection
(MOI 0.1). Following filtration, concentration, and purification (20% sucrose cushion in PBS),
supernatants were spotted on glass coverslips and left to adsorb to the glass for 15 min at 37˚C.
Particles were blocked without fixation for 1 h in DMEM + 10% FBS followed by 1 h staining
with 1˚ antibody recognizing the RABV G protein and Alexa Fluor 488-conjugated 2˚ anti-
body (green). Particles were washed 3 times with DMEM for 5 min per wash prior to and after
2˚ antibody staining.
For immunofluorescence of dissociated SCG or M compartment axons, cells were fixed
in 4% PFA at RT for 10 min, permeabilized in 0.25% Triton X-100 for 20 min at RT, and
blocked in 3% BSA-PBS for 1 h. FITC-conjugated anti-RABV (N) antibody was diluted in 3%
BSA-PBS and added to cells for 1 h followed by three 5 min washes in PBS + 0.05% Tween.
DAPI was added to dissociated SCG in the third wash for 5 min.
Retrograde infection in tri-chambers
Unless otherwise specified, N compartment axons were either untreated (appropriate
solvent added to control), pretreated with IFNβ or IFNγ for 24 h, or pretreated with protein
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synthesis inhibitors for 1 h prior to axonal infection with RABV P-mCherry (see Fig 2A). N
compartment axons were infected with 105 ffu of RABV P-mCherry unless otherwise speci-
fied. At 5 hpi, green lipophilic dye (DiO) was added to the N compartment to label the con-
nected cell bodies in the S compartment. Using live cell imaging, the entire S compartment
was tile imaged at designated times post axonal infection for P-mCherry expression (red)
and DiO staining (green). Total numbers of green and dual-colored cell bodies were counted
manually using NIS Elements Advanced Research software (Nikon). The average number of
DiO-positive cell bodies counted per chamber (n = 150 chambers) was 1981 cells. The %
infected cell bodies refers to the percentage of DiO-positive cell bodies that were also P-
mCherry-positive.
For protein synthesis inhibitor experiments, the inhibitors and virus inoculum were washed
out and removed from the N compartment at 5 hpi, at which point the N compartment was
replaced with fresh neurobasal media. For the IFN experiments, IFN and virus inoculum were
not removed from the N compartment, and media was not replaced throughout the duration
of the experiment.
Single particle tracking in tri-chambers
For RABV particle tracking, N compartment axons were either untreated (control), pretreated
with IFNβ or IFNγ for 24 h, or pretreated with 100 μM emetine 1 h prior to RABV P-mCherry
infection in N (105 ffu). Time lapse imaging was used to visualize and count the number of
RABV particles that moved from N into M between 2–4 hpi. Each movie captured one field of
view (FOV) for 15 seconds (sec) at> 10 frames/sec. For Rab5 and Rab7 particle tracking, S
compartment cell bodies were transduced with adenoviruses expressing either Venus-Rab5 or
Venus-Rab7. At 4 days post transduction, the N compartment axons were either untreated or
treated with 100 μM emetine (in the absence of RABV infection). At 2–4 h post emetine treat-
ment, Rab motility was recorded in N compartment axons. The percentage of moving Rab par-
ticles to total particles (moving + stationary) was calculated per axon for a minimum of 22
axons per condition.
Image processing and analysis
Imaging was conducted on a Nikon Eclipse Ti inverted epifluorescence microscope using a
Photometrics CoolSNAP ES2 CCD camera or an Andor iXon3 EMCCD camera (particle
tracking). Images and movies were processed using NIS Elements Advanced Research software
(Nikon) and Fiji Image J [55]. Comparative images were captured with the same exposure
times. Brightness and contrast adjustments were applied to the entire image, and alternations
were applied equally across comparative images. For particle intensity analysis, the Fiji thresh-
old feature was used to identify red particles. The analyze particle feature was then used to
measure the maximum gray value for each red particle identified in the threshold. Particle
intensity (S1B Fig) represents the mean maximum gray value across all particles analyzed for
each recombinant strain. To determine the percentage of particles containing G, measure-
ments were redirected from the red threshold to the green (anti-G) channel. A maximum gray
value was obtained in the green channel at the location of each particle in the red channel. A
red particle was considered dual-colored, if the maximum green intensity was above the back-
ground signal. To analyze particle transport, Fiji Z project was used to construct maximum
intensity projections of individual fields of view that contained moving viral particles. Each
maximum intensity projection was combined into a stack with its original movie file using the
Fiji concatenate feature. The transport distance of each particle was measured by manually
tracing the course of each track in the concatenated stack using the Fiji segmented line feature.
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Particles were excluded from the transport distance analyses if they entered or exited the field
of view during the 15 s movie. Kymographs were created from single particle tracks using the
Fiji KymographBuilder plugin. For velocity measurements, particle tracks were separated into
segments of constant velocity as described previously [56].
Statistical analysis
All data were analyzed with Graphpad Prism 7.04 (GraphPad Software, La Jolla California
USA, www.graphpad.com). Figure legends specify the statistical test applied for each analysis,
as well as the measure of dispersion about the mean and the number of replicates used. Experi-
ments were repeated three times unless otherwise specified. Standard deviation (SD) is
reported as the error for all measurements in the results section except for particle velocities
and particle track lengths. For those population level measurements, the standard error of the
mean (SEM) is reported. Differences were considered statistically significant when p values
were less than 0.05 (p< 0.05, p< 0.01,  p< 0.001, p< 0.0001).
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Supporting information
S1 Fig. RABV P-mCherry particles contain an average of 116 copies of the P protein. (A)
PRV UL25-mCherry, RABV P-mCherry, and PRV mCherry-UL35 particles from sucrose-
purified supernatants (scale bars = 5 μm). (B) Quantification of particle intensity (arbitrary
units (AU)) based on mCherry brightness across individual particles of PRV UL25-mCherry
(n = 815), RABV P-mCherry (n = 825), and PRV mCherry-UL35 (n = 841). Error bars indicate
mean maximum particle intensity + SD. (C) Table listing the approximate average copy num-
ber per particle of RABV P and PRV pUL35. Protein copy number was extrapolated from the
known PRV pUL25 copy number (60 copies) by comparing the mCherry fluorescence emis-
sion intensities between virus strains.
(TIF)
S2 Fig. Axonal IFNβ or IFNγ treatment induces STAT1 phosphorylation in axons or cell
bodies, respectively. N compartment axons were treated with IFNβ or IFNγ for 24 h. S and N
compartments were lysed separately, and proteins were separated by SDS-PAGE on 4–12%
gradient gels. Phosphorylated STAT1 (P-STAT1) levels were determined in the S and N com-
partments by western blotting. Symbols indicate the presence (+) or absence (-) of IFN in the
N compartment. Β-actin served as a loading control.
(TIF)
S3 Fig. RABV P-mCherry particles that are transported retrograde to the M compartment
co-stain with RABV nucleocapsid (N) protein. (A) Experimental setup for immunofluores-
cence (IF) staining of RABV particles in the M compartment. (B) IF staining of P-mCherry-
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positive particles (red) using FITC-conjugated anti-RABV antibody targeting the N protein.
White arrows in merge panel indicate co-localization between P-mCherry signal and anti-N
protein staining in fixed M compartment axons at 4 h post infection (scale bars = 20 μm). (C)
RABV N protein in SCG cell bodies (CB) at 24 h post axonal infection. Protein lysates were
separated using SDS-PAGE, and N protein levels were determined by western blotting. Sym-
bols indicate the presence (+) or absence (-) of RABV infection in N.
(TIF)
S4 Fig. Emetine acts locally in axons to inhibit retrograde RABV infection in a dose-depen-
dent manner. (A) Quantification of % infected cell bodies at 24 h post axonal infection in
the absence or presence of 10 μM, 50 μM, or 100 μM emetine in N. (B) Quantification of %
infected cell bodies at 24 h post direct S compartment infection in the absence or presence of
100 μM emetine in N. Emetine was added to N, 1 h prior to infection in S. Emetine was washed
out at 5 hpi. Black dots represent individual tri-chambers. Horizontal lines and error bars rep-
resent mean ± SD with p = 0.004, p< 0.0001 using one-way ANOVA (ns = not signifi-
cant using unpaired t-test).
(TIF)
S5 Fig. Emetine is non-toxic when isolated axons are exposed for 6 h. (A) Brightfield
images of cell bodies and axons at 24 h after a 6 h treatment with emetine (100 μM) or vehicle
in N (scale bars = 100 μm). Emetine was washed out of the N compartment at 6 h post treat-
ment, and fresh media was added. (B) Experimental setup for live/dead SYTOX cell assay:
DiI was added to the N compartment axons to label connected cell bodies in red. Emetine
was added to the N compartment for 6 h (or to the S compartment for 24 h as a positive con-
trol for cell death). Emetine was washed out of axons after 6 h. At 6 or 24 h, cell bodies were
stained with SYTOX green nucleic acid stain (5 nM) for 10 min and imaged. Representative
images show cell bodies in the S compartment at 6 h after emetine treatment in N and 24 h
after emetine treatment in S (scale bars = 100 μm). (C) Table indicates percentage of dead
cell bodies at 6 h or 24 h after a 6 h emetine treatment in N versus a 6 h or 24 h emetine treat-
ment in S. The percentage of dead cells refers to the percentage of connected cell bodies
(DiI-positive) that are stained with SYTOX (No treatment, n = 3; Emetine in N imaged at 6
h, n = 3; Emetine in N imaged at 24 h, n = 1; Emetine in S imaged at 6 h, n = 1; Emetine in S
imaged at 24 h, n = 2).
(TIF)
S6 Fig. RABV particles enter axons within 60 min. (A) Experimental setup for entry assay.
(B) Quantification of % infected cell bodies at 24 hpi when N compartment axons were incu-
bated with RABV inoculum for 1 to 300 minutes. The virus inoculum was removed following
the designated incubation period, and the axons were washed three times with PBS to remove
extracellular particles. Black dots represent individual tri-chambers. Horizontal lines and error
bars represent mean ± SD with p = 0.02, p< 0.0001 using one-way ANOVA (ns = not sig-
nificant).
(TIF)
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